We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Centers for Medicare & Medicaid Services (CMS) Administrator Mark McClellan July 20 addressed the opposition his agency has seen to its proposals to change the Medicare inpatient prospective payment system in 2007.
Louisiana will become the first state to increase the fees pharmacists receive every time they fill Medicaid prescriptions with generic drugs, after Louisiana’s governor Kathleen Blanco signed legislation to offset federal Medicaid reimbursement cuts.
The Department of Justice (DOJ) and Medtronic announced July 18 the firm will pay the government $40 million to settle a civil suit alleging that the firm's Sofamor Danek division paid kickbacks to healthcare professionals to induce them to use Medtronic's spinal products.
A recent guidance issued by the Centers for Medicare & Medicaid (CMS) has industry groups worrying whether reimbursements for their products could be cut -- or even eliminated.
Lawmakers and government regulators need to consider the cost savings that devices and diagnostics offer to the U.S. healthcare system when making decisions that could affect patients’ access to new treatments, say industry leaders and at least one Senate lawmaker.
Proponents of the Centers for Medicare & Medicaid Services’ (CMS) prescription drug plan and its detractors are engaging in a statistical battle to make their case for the impact of Part D on prescription drug prices, with industry groups and the agency pitted against consumer advocates.
A recent policy decision by the Centers for Medicare & Medicaid Services (CMS) “simplifies physician billing for remote monitoring technologies” and will benefit thousands of cardiac patients across the U.S., devicemaker Medtronic said June 16.
The Centers for Medicare & Medicaid Services (CMS) should delay implementing its proposed changes to the hospital inpatient prospective payment system (IPPS) to allow more time for stakeholders to evaluate their impact on the device industry, say two leading associations.
Devicemakers are pushing for legislative reforms to rein in the administrative and other fees collected by group purchasing organizations (GPOs) that contribute to Medicare cost pressures, according to an industry expert.